Nektar Therapeutics
NKTR43.940USD
-0.520-1.17%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
863.53MMarket Cap
LossP/E TTM
More Details of Nektar Therapeutics Company
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar Therapeutics Info
Ticker SymbolNKTR
Company nameNektar Therapeutics
IPO dateMay 03, 1994
CEORobin (Howard W)
Number of employees61
Security typeOrdinary Share
Fiscal year-endMay 03
Address455 Mission Bay Boulevard South
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94158
Phone18554826587
Websitehttps://www.nektar.com/
Ticker SymbolNKTR
IPO dateMay 03, 1994
CEORobin (Howard W)
Company Executives of Nektar Therapeutics
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.73K
+11.72%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
16.66K
+9.96%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.73K
+11.72%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
16.66K
+9.96%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
6.28%
The Vanguard Group, Inc.
4.66%
Susquehanna International Group, LLP
4.55%
Morgan Stanley & Co. LLC
4.34%
Farallon Capital Management, L.L.C.
3.89%
Other
76.28%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
6.28%
The Vanguard Group, Inc.
4.66%
Susquehanna International Group, LLP
4.55%
Morgan Stanley & Co. LLC
4.34%
Farallon Capital Management, L.L.C.
3.89%
Other
76.28%
Shareholder Types
Shareholders
Proportion
Hedge Fund
31.87%
Investment Advisor
21.99%
Investment Advisor/Hedge Fund
8.86%
Research Firm
7.04%
Pension Fund
0.76%
Individual Investor
0.70%
Venture Capital
0.69%
Bank and Trust
0.02%
Other
28.08%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
342
9.79M
51.46%
-2.29M
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
1.28M
6.71%
+1.28M
--
Jul 01, 2025
The Vanguard Group, Inc.
729.49K
3.84%
-91.15K
-11.11%
Jun 30, 2025
Susquehanna International Group, LLP
221.89K
1.17%
+184.74K
+497.33%
Jun 30, 2025
Emerald Advisers LLC
143.29K
0.75%
+389.00
+0.27%
Sep 30, 2025
Millennium Management LLC
649.03K
3.41%
+496.45K
+325.35%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
297.81K
1.57%
-576.08K
-65.92%
Jun 30, 2025
Nantahala Capital Management, LLC
709.76K
3.73%
+190.49K
+36.68%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Dorsey Wright Healthcare Momentum ETF
4.55%
Simplify Health Care ETF
3.22%
Simplify Propel Opportunities ETF
2.69%
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.48%
Invesco NASDAQ Future Gen 200 ETF
1.17%
Invesco Dorsey Wright SmallCap Momentum ETF
0.95%
iShares U.S. Pharmaceuticals ETF
0.46%
Invesco RAFI US 1500 Small-Mid ETF
0.13%
Schwab U.S. Small-Cap ETF
0.03%
View more
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion4.55%
Simplify Health Care ETF
Proportion3.22%
Simplify Propel Opportunities ETF
Proportion2.69%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.48%
Invesco NASDAQ Future Gen 200 ETF
Proportion1.17%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.95%
iShares U.S. Pharmaceuticals ETF
Proportion0.46%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.13%
Schwab U.S. Small-Cap ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 04, 2025
Merger
15→1
Date
Type
Ratio
Jun 04, 2025
Merger
15→1
FAQs
Who are the top five shareholders of Nektar Therapeutics?
The top five shareholders of Nektar Therapeutics are:
BVF Partners L.P. holds 1.28M shares, accounting for 6.71% of the total shares.
The Vanguard Group, Inc. holds 729.49K shares, accounting for 3.84% of the total shares.
Susquehanna International Group, LLP holds 221.89K shares, accounting for 1.17% of the total shares.
Emerald Advisers LLC holds 143.29K shares, accounting for 0.75% of the total shares.
Millennium Management LLC holds 649.03K shares, accounting for 3.41% of the total shares.
BVF Partners L.P. holds 1.28M shares, accounting for 6.71% of the total shares.
The Vanguard Group, Inc. holds 729.49K shares, accounting for 3.84% of the total shares.
Susquehanna International Group, LLP holds 221.89K shares, accounting for 1.17% of the total shares.
Emerald Advisers LLC holds 143.29K shares, accounting for 0.75% of the total shares.
Millennium Management LLC holds 649.03K shares, accounting for 3.41% of the total shares.
What are the top three shareholder types of Nektar Therapeutics?
The top three shareholder types of Nektar Therapeutics are:
BVF Partners L.P.
The Vanguard Group, Inc.
Susquehanna International Group, LLP
BVF Partners L.P.
The Vanguard Group, Inc.
Susquehanna International Group, LLP
How many institutions hold shares of Nektar Therapeutics (NKTR)?
As of 2025Q3, 342 institutions hold shares of Nektar Therapeutics, with a combined market value of approximately 9.79M, accounting for 51.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.10%.
What is the biggest source of revenue for Nektar Therapeutics?
In FY2024, the -- business generated the highest revenue for Nektar Therapeutics, amounting to -- and accounting for --% of total revenue.
